First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies
Status:
Completed
Trial end date:
2018-08-09
Target enrollment:
Participant gender:
Summary
This is a Phase 1, first-in-human, open-label, non-randomized, dose escalation, trial to
explore the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical
activity signals of MSC2363318A.